Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
H. Burch, L. Wartofsky.
Graves’ ophthalmopathy: current concepts regarding pathogenesis and management.
Endocr Rev, 14 (1993), pp. 747-793
[2.]
C.A. Gorman.
Temporal relationship between onset of Graves’ ophthalmopathy and the diagnosis of thyrotoxicosis.
Mayo Clin Proc, 58 (1983), pp. 515-519
[3.]
M.F. Prummel, W.M. Wiersinga.
Medical management of Graves’ ophthalmopathy.
Thyroid, 3 (1995), pp. 231-234
[4.]
M.F. Prummel, W.M. Wiersinga, M.P. Mourits, L. Koornneef, A. Berghout, R. Vander Gaag.
Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy.
Arch Intern Med, 150 (1990), pp. 1098-1101
[5.]
M.F. Prummel, W.M. Wiersinga, M.P. Mourits, L. Koornneef, A. Berghout, R. Vander Gaag.
Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism.
Acta Endocrinol (Copenh), 121 (1989), pp. 185-189
[6.]
R. Volpé.
Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulatig thyrocyte-immunocyte signalling: a review.
Thyroid, 2 (1994), pp. 217-223
[7.]
C. Marcocci, L. Bartalena, F. Bogazzi, G. Bruno-Bossio, A. Pinchera.
Relationship between Graves’ ophthalmopathy and type of treatment of Graves’ hyperthyroidism.
Thyroid, 2 (1992), pp. 171-178
[8.]
I. Todd, R. Pujol-Borrell, L.J. Hammond, J.M. Nally, M. Feldmann, G.F. Botazzo.
Enhancement of thyrocyte HLA class II expresion by thyroidstimulating hormone.
Clin Exp Immunol, 69 (1987), pp. 524-531
[9.]
A.P. Weetman.
The immunomodulatory effects of antithyroid drugs.
Thyroid, 2 (1994), pp. 145-146
[10.]
L.J. DeGroot.
Radioiodine and the immune system.
Thyroid, 7 (1997), pp. 259-264
[11.]
A.M. McGregor, M.M. Petersen, R. Capiferri, D.C. Evered, B.R. Smith, R. Hall.
Effects of radioiodine on thyrotropin binding inhibiting immunoglobulins in Graves’ disease.
Clin Endocrinol (Oxf), 11 (1979), pp. 437-444
[12.]
M. Soliman, E. Kaplan, A. Abdel-Latif, N. Scherberg, L.J. DeGroot.
Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients’ T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?.
J Clin Endocrinol Metab, 80 (1995), pp. 2312-2321
[13.]
T.W.A. De Bruin, A. Pathwardhan, R.S. Brown, L.E. Braverman.
Graves’ disease: changes in TSH receptor and anti-microsomal antibodies after thyroidectomy.
Clin Exp Immunol, 72 (1988), pp. 481-485
[14.]
R.S. Bahn, C.A. Gorman.
Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy.
Endocrinol Metab Clin North Am, 16 (1987), pp. 391-407
[15.]
L. Bartalena, A. Pinchera, C. Marcocci.
Management of Graves’ ophthalmopathy: reality and perspectives.
Endocr Rev, 21 (2000), pp. 168-199
[16.]
L. Bartalena, C. Marcocci, F. Bogazzi, M. Panicucci, A. Lepri, A. Pinchera.
Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism.
N Engl J Med, 321 (1989), pp. 1349-1352
[17.]
L. Bartalena, C. Marcocci, F. Bogazzi, L. Minetti, M.L. Tanda, E. Dell’Unto, et al.
Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy.
N Engl J Med, 338 (1998), pp. 73-78
[18.]
C. Marcocci, G. Bruno-Bossio, L. Manetti, M.L. Tanda, P. Miccoli, P. Iacconi, et al.
The course of ophthalmopathy is not influenced by near total thyroidectomy: a case-control study.
Clin Endocrinol (Oxf), 51 (1999), pp. 503-506
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición